Similarly simultaneous determination of metronidazole benzoate (MB), diloxanide furoate (DF), methyl paraben (MPn) and propyl paraben (PPn) in suspension was studied (Mishal and Sober, 2005) in which mobile phase, a phosphate buffer- acetonitrile mixture (70:30, v/v) adjusted to pH of 2.
Separation and estimation of diloxanide furoate and metronidazole in solid dosage form using packed column supercritical fluid chromatography.
Stability indicating Reversed-phase liquid chromatographic determination of metronidazole benzoate and diloxanide furoate as bulk drug and in suspension dosage form.
This can be accomplished by treatment with either iodoquinol, paromomycin, or diloxanide furoate.
Treatment of ALA (a) Drug Adult dosage Side effects Metronidazole 750 mg tid X 7-10 days ~10%: headache, dizziness, nausea, anorexia, vomiting <1%: ataxia, seizures, paraesthesias, peripheral neuropathy, disulfiram-like reaction with alcohol, metallic taste, vaginal candidiasis -or- Tinidazole 2 g/d divided tid X 3 days Similar to metronidazole, but typically better tolerated -followed by- Iodoquinol 650 mg tid X 20 days Optic neuritis with long-term use; generally well tolerated -or- Paromomycin 25-35 mg/kg/d divided tid 1-10%: diarrhea, X 7 days nausea, vomiting, abdominal cramps, heartburn <1%: headache, vertigo, eosinophilia, rash, pruritus, ototoxicity -or- Diloxanide furoate 500 mg tid X 10 days Flatulence, nausea, vomiting, pruritus, urticaria (a) ALA, amebic liver abscess.
The current treatment modalities for intestinal protozoan parasites include metronidazole, iodoquinol, diloxanide
furoate, paromomycin, chloroquine, and trimethoprim-sulphamethoxazole (39).